VST-Bio Corp.

Results show statistically significant decreases in stroke volume, edema, and necrotic area versus controls SAN DIEGO, Feb. 12, 2024 /PRNewswire/ -- VST Bio Corp. a leader in the development of innovative biologics to treat acute and chronic cardiovascular disease, presented data from a recent large animal study performed by VST Bio and Yale University demonstrating that a single iv bolus of VST-002 led to meaningful reduction in brain damage and improved function in an advanced model of ischemic stroke. Dr. Federico Corti, from the Cardiovascular Research Center of Yale University, presented data which showed that a single bolus of humanized anti-Syndecan 2 antibody (VST-002), administered either 3 hours or 6 hours after ischemia led to ~60% reduction of stroke damage as visualized by magnetic resonance imaging, with all measures being statistically significant over control animals. Histological analysis at 72 hours post-stroke confirmed a significant reduction of edema and area of necrosis in both early and delayed therapy groups. These findings indicate that anti-Sdc2 mAb promotes neuroprotection and suggest that this therapy could be used both in patients undergoing early reperfusion as well as outside the current reperfusion window guidelines. Furthermore, the treatment was safe with no observed toxicities. The study was performed by an independent CRO, blinded to treatment assignment. VST Bio Chief Executive Officer Krisztina Zsebo, PhD, said, "VST-002 human antibody therapy is being initially developed to treat ischemic stroke patients. The current standard-of-care is either thrombolytic therapy when given within the first 4.5 hours of stroke, or thrombectomy given within 24 hours. However, many hospitals don't offer thrombectomy because it requires specialist doctors, leaving the majority of patients ineligible for conventional treatment. VST-002 may offer an additional path to preserve brain function and improve recovery after ischemic stroke". Prof. Dr. Michael Simons of Yale University, chair of the Scientific Advisory Committee, commented: "The humanized anti-Syndecan 2 monoclonal antibody therapy has shown consistent efficacy in normalizing vascular patency in various preclinical assays and models while preserving normal vasculature1,2. A normalization of vascular permeability in acute stroke results in reduced local and systemic inflammation as well as decreased edema formation. As a result, there is a significant reduction of stroke size, even when VST-002 antibody therapy is initiated late after the onset of stroke. Reducing edema, inflammation, and secondary injury after stroke could have a meaningful benefit for stroke patient outcomes." About VST Bio VST Bio Corp., headquartered in San Diego, California, is developing vascular biologic therapies to treat acute cardiovascular disease. VST-002 antibody therapies are one of the Company's biotherapeutic product candidates in clinical development. For more information, visit . References: F Corti, E Ristori, F Rivera-Molina, D Toomre, J Zhang, J Mihailovic, ZW Zhuang, M Simons, "Syndecan-2 selectively regulates VEGF-induced vascular permeability.", Nat Cardiovasc Res. 2022 May; 1(5): pg 518-528 F Corti F and M Simons. "Modulation of VEGF receptor 2 signaling by protein phosphatases.", Pharmacol Res. 2017 Jan; 115: pg 107-123. Media Contact: Rebecque Laba (858) 663-8641 [email protected] Investor Contact: Krisztina Zsebo, Ph.D., Chief Executive Officer 619-889-5199 [email protected] Logo -

PBIO Acknowledges Rapidly Emerging Demand Potential for UltraShear Nanoemulsions for Transformation of Diverse Major Markets, with Recently Announced Readiness and Scaling Plans SOUTH EASTON, MA / ACCCESSWIRE / September 22, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty process development and testing services to the global nutraceuticals, cosmeceuticals, food/beverage, biotherapeutics, and other industries, and the Veterans Service Team ("VST") ( ), a self-funded, 501(c)3 non-profit company dedicated to the support and wellness of active duty and former members of all branches of the US Military and US Coast Guard, today announced that VST has increased its existing purchase order with PBIO by 10-fold (from 500 to 5,000 bottles), effective immediately. PBIO's Ultra Shear TechnologyTM (UltraShearTM or USTTM) platform allows oil-soluble active molecules like CBD to be prepared into nanoemulsions of vanishingly tiny oil droplets in water that ensure rapid absorption and unparalleled bioavailability of the CBD (or other active ingredients) into the water-based biochemistry of human bodies. The PBIO-VST partnership offers VST membership exclusive access to custom-designed, hemp-derived, UltraShear-processed nanoemulsions of CBD oil in water ("Nano-CBD"), providing unparalleled speed of action and reliable dosage delivery. VST is initially launching their uniquely differentiated UltraShear Nano-CBD Topical Spray, with plans for its sister product, UltraShear Nano-CBD Oral Spray, to quickly follow. In a June 2023 press release announcing the new, five-year partnership between VST and PBIO, Mr. Howard Zall, COO of VST, explained that a leading-quality CBD product with world class speed and completeness of dose delivery and effectiveness had been the most important new offering that VST was targeting in 2023, to help address and manage a diversity of critical needs for their members. Mr. Zall stated they had determined that PBIO's UltraShear Technology was the world's leading platform for developing highly effective nanoemulsions of CBD in either a topical or oral spray. They were (and are) excited to partner with PBIO, to soon introduce to their membership the first product to emerge from this collaboration: a revolutionary, all-natural, preservative-free, highly potent, UltraShear nanoemulsified CBD topical spray. Mr. John B. Hollister, Director of Marketing and Sales, commented: "Yesterday we announced the successful expansion of internal capabilities to ensure the fulfillment of existing orders, starting in early October. Today we are announcing a 10-fold increase in the number of bottles of one of these existing orders. Although this request is a significant increase, it is important to note that our VST partner has advised us that this may be the "tip of the iceberg", and that PBIO needs to be ready to respond to such large orders in the near future, both often and quickly." Mr. Richard T. Schumacher, President and CEO of PBIO, concluded: "As stated in our June announcement, VST believes their membership will exceed two million of the nearly 18 million active-duty personnel and veterans within five years. PBIO and VST estimate that PBIO's revenue from this relationship will significantly grow year-over-year, from initial annual revenue of about $1.5M to as much as $15M in the fifth year of the agreement. These projections are for Nano-CBD products sales only (both topical and oral), which the companies believe will be generated from sales of up to 50,000 spray bottles in Year 1 to approximately 500,000 spray bottles in Year 5. PBIO investors and VST members can expect to hear much more about additional UltraShear processed products developed and offered through VST in the months ahead." About Veterans Service Team (VST) The VST mission is to serve the roughly 18 million current members and veterans of the US Armed Services and Coast Guard with education, support services, and a potent collection of diverse, carefully selected health and wellness products. VST is in the early stages of building membership, through which they expect to increase VST to over 2 million members in the next five years. VST's founder, Captain George Ackerson, is an exceptional individual with a strong, diverse background. As a seasoned business professional and former Military Officer, he brings a wealth of experience to the table. Notably, Captain Ackerson served in Vietnam as a Special Ops Scout Helicopter Pilot, demonstrating his bravery and commitment to service. Captain Ackerson's passion lies in supporting fellow veterans by leveraging his extensive knowledge and expertise. With a deep understanding of health and wellness, he strives to make a meaningful impact and empower others through innovative approaches. About Pressure BioSciences, Inc. Pressure BioSciences, Inc. (OTCQB:PBIO) is a global leader in providing innovative, broadly enabling, high pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical, and agrochemical, as well as food and beverage manufacturing. Our products utilizeboth constant and alternating pressure. Our patented enabling technology platform, Pressure Cycling Technology (PCT), utilizes alternating cycles of pressure to control bio-molecular interactions (such as cell lysis and biomolecule extraction) safely and reproducibly. PCT-based products are beginning to be widely used for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterrorism applications. We have recently expanded our market opportunities with the acquisition of the BaroFold™ patented technology platform, allowing us to enter the bio-pharma contract services and GMP manufacturing equipment sector. We have also developed the scalable and high-efficiency pressure-based UltraShear Technology™ (UltraShear™) platform, which allows for the creation of stable nanoemulsions of otherwise immiscible fluids. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room temperature-stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. Our commitment to innovation and cutting-edge technology has established PBIO as a leader in the high-pressure industry, providing unique and effective solutions to our customers. Forward Looking Statements This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should,""could,""would," "expects," "plans," "intends,""anticipates," "believes," estimates,""predicts," "projects,""potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law. For more information about PBIO, VST, and this press release, please click on the following website links: Please visit us on Facebook, LinkedIn, and Twitter. Press Contacts: Richard T. Schumacher, President & CEO (508) 230-1828 (T) John B. Hollister, Director of Sales and Marketing (805) 908-5719 (T) Howard Zall, COO, Veterans Service Team (303) 520-1533 (T) Captain George Ackerson, President, Veterans Service Team (406) 621-0104 (T) SOURCE: Pressure BioSciences Inc. View source version on accesswire.com:

VST-Bio's Collaborators Present Preclinical Trial Results at the American Heart Association International Stroke Conference in Dallas. SAN DIEGO, Feb. 10, 2023 /PRNewswire/ -- VST-Bio Corp. a leader in the development of innovative biologics to treat acute and chronic cardiovascular disease, presented data from a recent large animal study performed by VST-Bio and Yale University demonstrating that a single iv bolus of VST-002 led to meaningful reduction in brain damage and improved function in an advanced model of ischemic stroke. Dr. Federico Corti, from the Cardiovascular Research Center of Yale University, presented data which showed that a single bolus of humanized anti-Syndecan 2 antibody (VST-002), led to 60% reduction of stroke damage as visualized by magnetic resonance imaging, with all measures being statistically significant over control animals. Furthermore, the treatment was safe with no observed toxicities. The study was performed by an independent CRO, blinded to treatment assignment. VST-Bio Chief Executive Officer Eric Duckers, MD PhD, said, "The VST-002 human antibody therapy is being initially developed to treat ischemic stroke patients (Cerebrovascular Accident – CVA) who present late at the medical centers, when conventional therapy is no longer effective. The current standard-of-care is thrombolytic therapy to resolve blood clots, but unfortunately is only effective when given within the first few hours of stroke, leaving 90% of all patients ineligible or non-responsive to conventional treatment. VST-002 may offer an alternative path to preserve brain function and improve recovery after ischemic stroke". "In light of these positive data on our humanized antibody therapy, we expect to meet our internal timeline to complete our submission to the FDA for our first indication for Late-Stroke, and to initiate clinical trials in 2024." Prof. Dr. Michael Simons of Yale University, chair of the Scientific Advisory Committee, commented: "The humanized anti-Syndecan 2 monoclonal antibody therapy has shown consistent efficacy in normalizing vascular patency in various preclinical assays and models 1,2. A normalization of vascular permeability in acute stroke results in reduced local and systemic inflammation as well as decreased edema formation. As a result, there is a significant reduction of stroke size, even when VST-002 antibody therapy is initiated late after the onset of stroke. Reducing edema, inflammation, and secondary injury after stroke could have a meaningful benefit for stroke patient outcomes." About VST-Bio VST-Bio Inc., headquartered in San Diego, California, is developing vascular biologic therapies to treat acute cardiovascular disease. VST-002 antibody therapies are one of the Company's biotherapeutic product candidates in clinical development. For more information, visit . References: F Corti, E Ristori, F Rivera-Molina, D Toomre, J Zhang, J Mihailovic, ZW Zhuang, M Simons, "Syndecan-2 selectively regulates VEGF-induced vascular permeability.", Nat Cardiovasc Res. 2022 May; 1(5): pg 518-528 F Corti F and M Simons. "Modulation of VEGF receptor 2 signaling by protein phosphatases.", Pharmacol Res. 2017 Jan; 115: pg 107-123. Media Contact: Rebecque Laba (858) 665-2009 [email protected] Investor Contact: Eric Duckers, Chief Executive Officer (858) 665-8722 [email protected] SOURCE VST Bio Corporation